Investigational Medicine

RETATRUTIDE

The Triple-Agonist revolutionizing metabolic therapy.

24.2%
Mean Weight Loss

At 48 Weeks (12mg)

3
Target Receptors

GLP-1 • GIP • Glucagon

86%
Liver Fat Normalized

In NAFLD Patients

The Power of Three ("GGG")

Unlike current drugs that target one or two pathways, Retatrutide hits three. The addition of Glucagon is the key differentiator, turning the body's metabolism into a furnace.

🧠

GLP-1

The Appetite Controller

Found in Wegovy & Ozempic.

  • Increases Satiety
  • Slows Digestion
  • Stimulates Insulin
🍬

GIP

The Synergist

Found in Mounjaro (with GLP-1).

  • Improves Tolerability
  • Potentiates Insulin
  • Fat Metabolism
🔥

Glucagon

The Metabolic Furnace

The Retatrutide Advantage.

  • Burns Energy (REE)
  • Clears Liver Fat
  • Protects Kidneys

Unprecedented Weight Loss

Phase 2 Clinical Trial Results (NEJM 2023)

Weight Loss Over Time (48 Weeks)

Participants on the 12mg dose saw rapid, sustained weight loss, not yet plateauing at week 48.

The Competitive Landscape

Comparing maximum reported efficacy across separate pivotal trials. Retatrutide approaches bariatric surgery levels.

Liver Fat Obliteration

For patients with Non-Alcoholic Fatty Liver Disease (NAFLD), Retatrutide was remarkably effective.

>80%

Mean Relative Reduction

Safety & Tolerability

Side effects are largely gastrointestinal and dose-dependent. Note the unique cardiac signal (heart rate increase) being monitored.

Path to Approval

Phase 2 Completed
Published in NEJM. Established efficacy and dosing.
TRIUMPH Phase 3
Four pivotal trials recruiting thousands of patients globally.
?
FDA Filing
Potential approval and market launch.